Olympus duodenoscopes.
Contamination & superbug infection litigation.
Pre-MDL litigation against Olympus Medical Systems Corporation alleging that the company's reusable duodenoscopes are inadequately designed for safe reprocessing, leading to bacterial contamination, superbug transmission, and patient infection — including sepsis and death.
The plaintiff theory.
The device. The contamination.
The Olympus duodenoscope litigation involves claims against Olympus Medical Systems Corporation brought by patients who developed serious infections following procedures using Olympus reusable duodenoscopes — specialized endoscopic devices used in approximately 700,000 ERCP procedures annually in the United States. The complaint at the center of the litigation is design-based: the devices contain a complex elevator mechanism that cannot be effectively cleaned between patients using standard reprocessing protocols, allowing bacterial colonization that transmits between patients.
The infections at issue are not ordinary post-procedure complications. They are serial cross-contamination events in which one patient's bacteria, including multidrug-resistant organisms like CRE (carbapenem-resistant Enterobacteriaceae), are transmitted to subsequent patients through inadequately sterilizable scopes. Documented outbreaks have occurred at major medical centers including UCLA, Vanderbilt, and Providence. Reported injuries include bloodstream infection, sepsis, organ damage, and death.
The regulatory record is unusually strong. Olympus pleaded guilty in 2018 to failing to report adverse events involving infections from its scopes and paid an $85 million fine. In June 2025, the FDA issued an import alert blocking 58 Olympus device models from entering the United States. In October 2025, Olympus issued an Urgent Field Safety Notice acknowledging that current reprocessing protocols for the TJF-Q190V, TJF-Q290V, and TJF-Q170V duodenoscope models are insufficient to prevent infection.
Procedural posture.
No MDL yet. State and federal cases proceeding individually.
No federal multi-district litigation has been formed for Olympus duodenoscope infection cases as of early 2026. Cases are proceeding individually in state and federal courts across the United States. Litigation strategy varies by venue: some plaintiff firms are filing in federal court positioning for eventual MDL consolidation; others are pursuing state-court venue advantages, particularly in jurisdictions with favorable product liability law and stronger discovery rules.
The pre-MDL posture creates both a strategic opportunity and a complication for partner firms. Without a consolidated MDL, there is no shared discovery, no bellwether infrastructure, and no centralized leadership — but case-specific facts and venue selection matter materially in a way they do not in a mature MDL. The recent regulatory escalation (October 2025 Olympus safety notice, June 2025 FDA Import Alert) is the kind of pre-MDL triggering event that historically precedes JPML consolidation petitions.
Acquisition. Screening.
Retention.
Olympus duodenoscope intake requires careful eligibility screening on procedure history (the specific scope model used, date and facility of the ERCP), infection documentation (positive cultures, organism identification, treatment course), and the temporal relationship between procedure and infection. Cases involving CRE or other multidrug-resistant organisms, sepsis requiring ICU admission, or death are the strongest profiles. Hospital-record retrieval and identification of the specific scope used in a procedure are the operational chokepoints in this docket. We have built docket-specific intake protocols for the targeted record retrieval this litigation requires.
Acquisition runs across paid social, paid search, and connected TV, with creative built specifically for this docket and compliance review on every iteration. Every claimant flows through our multi-vendor fraud-detection suite — Anura, CHEQ, ActiveProspect, TrustedForm, Blacklist Alliance, and Plaid — before reaching the partner firm. Retained cases land directly in the firm's case management system in real time.
For partner firms holding Olympus dockets, we provide standing operational reporting on retained cases delivered, cost per qualified retention, and case-tier mix against your screening criteria. Strategy sessions cover docket-portfolio decisions: how to weight venue selection in the absence of an MDL, which case profiles are positioned best for bellwether status if consolidation eventually occurs, and how regulatory developments shift retention thresholds.
Start a conversation.
Speak with our team.
A LeadClient case-acquisition strategist will reach out to talk through your docket.